ZA200507742B - Use of 10-hydroxy-10, 11-dihydrocarbamazepine for the treatment of affective disorders - Google Patents
Use of 10-hydroxy-10, 11-dihydrocarbamazepine for the treatment of affective disorders Download PDFInfo
- Publication number
- ZA200507742B ZA200507742B ZA200507742A ZA200507742A ZA200507742B ZA 200507742 B ZA200507742 B ZA 200507742B ZA 200507742 A ZA200507742 A ZA 200507742A ZA 200507742 A ZA200507742 A ZA 200507742A ZA 200507742 B ZA200507742 B ZA 200507742B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- treatment
- represents hydrogen
- affective disorders
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 43
- 208000019022 Mood disease Diseases 0.000 title claims description 28
- BMPDWHIDQYTSHX-UHFFFAOYSA-N licarbazepine Chemical compound C1C(O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 BMPDWHIDQYTSHX-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 61
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 206010026749 Mania Diseases 0.000 claims description 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 19
- 239000004480 active ingredient Substances 0.000 claims description 14
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 14
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 229910052744 lithium Inorganic materials 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 229960005017 olanzapine Drugs 0.000 claims description 7
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 239000000935 antidepressant agent Substances 0.000 claims description 6
- 239000000164 antipsychotic agent Substances 0.000 claims description 6
- 229940005529 antipsychotics Drugs 0.000 claims description 6
- 230000001351 cycling effect Effects 0.000 claims description 6
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 6
- 206010015535 Euphoric mood Diseases 0.000 claims description 5
- 239000003693 atypical antipsychotic agent Substances 0.000 claims description 5
- 229940127236 atypical antipsychotics Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 4
- 229940005513 antidepressants Drugs 0.000 claims description 4
- 230000002743 euphoric effect Effects 0.000 claims description 4
- 229960001848 lamotrigine Drugs 0.000 claims description 4
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 claims description 4
- 229960000604 valproic acid Drugs 0.000 claims description 4
- 238000011418 maintenance treatment Methods 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 2
- 229940028937 divalproex sodium Drugs 0.000 claims description 2
- 230000001544 dysphoric effect Effects 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 230000000694 effects Effects 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 208000020925 Bipolar disease Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 208000027776 Extrapyramidal disease Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960003878 haloperidol Drugs 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 238000013461 design Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 2
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- 206010041243 Social avoidant behaviour Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 229960004341 escitalopram Drugs 0.000 description 2
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 229960002690 fluphenazine Drugs 0.000 description 2
- 229960004038 fluvoxamine Drugs 0.000 description 2
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 229940071264 lithium citrate Drugs 0.000 description 2
- WJSIUCDMWSDDCE-UHFFFAOYSA-K lithium citrate (anhydrous) Chemical compound [Li+].[Li+].[Li+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WJSIUCDMWSDDCE-UHFFFAOYSA-K 0.000 description 2
- INHCSSUBVCNVSK-UHFFFAOYSA-L lithium sulfate Inorganic materials [Li+].[Li+].[O-]S([O-])(=O)=O INHCSSUBVCNVSK-UHFFFAOYSA-L 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- 229960002296 paroxetine Drugs 0.000 description 2
- 229960004431 quetiapine Drugs 0.000 description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 2
- 229960001534 risperidone Drugs 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 229960002073 sertraline Drugs 0.000 description 2
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- RBTVSNLYYIMMKS-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate;hydrochloride Chemical compound Cl.CC(C)(C)OC(=O)N1CC(N)C1 RBTVSNLYYIMMKS-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 206010001497 Agitation Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010067371 Menopausal depression Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 201000009916 Postpartum depression Diseases 0.000 description 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003561 anti-manic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000228 antimanic agent Substances 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 208000025307 bipolar depression Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229960001816 oxcarbazepine Drugs 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229940106887 risperdal Drugs 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000967 thyroidotoxicity Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229940061414 trileptal Drugs 0.000 description 1
- 229940102566 valproate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45986403P | 2003-04-02 | 2003-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200507742B true ZA200507742B (en) | 2008-07-30 |
Family
ID=33131906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200507742A ZA200507742B (en) | 2003-04-02 | 2005-09-26 | Use of 10-hydroxy-10, 11-dihydrocarbamazepine for the treatment of affective disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20070010508A1 (fr) |
| EP (1) | EP1613329A1 (fr) |
| JP (1) | JP2006522064A (fr) |
| KR (1) | KR20050121235A (fr) |
| CN (1) | CN1767834A (fr) |
| AU (1) | AU2004226827B2 (fr) |
| BR (1) | BRPI0409151A (fr) |
| CA (1) | CA2520828A1 (fr) |
| IS (1) | IS8094A (fr) |
| MA (1) | MA27762A1 (fr) |
| MX (1) | MXPA05010614A (fr) |
| NO (1) | NO20055098L (fr) |
| NZ (1) | NZ542555A (fr) |
| RU (1) | RU2367440C2 (fr) |
| TN (1) | TNSN05246A1 (fr) |
| TW (1) | TW200502222A (fr) |
| WO (1) | WO2004087168A1 (fr) |
| ZA (1) | ZA200507742B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX366496B (es) * | 2005-05-06 | 2019-07-11 | Bial Portela & Ca Sa | Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso. |
| PT2380573E (pt) * | 2005-05-06 | 2015-06-11 | Bial Portela & Ca Sa | Acetato de eslicarbazepina e métodos de utilização |
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| GB2437078A (en) | 2006-04-11 | 2007-10-17 | Portela & Ca Sa | 10-Acyloxy-5H-dibenzo[b,f]azepine-5-carboxamides & their asymmetric hydrogenation to the chiral 10,11-dihydro derivatives |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| BRPI0907570A2 (pt) * | 2008-02-13 | 2019-09-24 | Targacept Inc | agonistas alfa7 nicotínico e antipsicóticos |
| ES2730800T3 (es) | 2009-02-03 | 2019-11-12 | Amunix Pharmaceuticals Inc | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| CN102188432B (zh) * | 2011-04-07 | 2012-05-23 | 江立富 | 一种用于防治癫痫的药物 |
| JP2013237676A (ja) * | 2013-06-26 | 2013-11-28 | Bial-Portela & Ca Sa | 酢酸エスリカルバゼピン及び使用方法 |
| US9896451B2 (en) | 2013-09-06 | 2018-02-20 | Nippon Soda Co., Ltd. | Method for producing endo-9-azabicyclo[3.3.1]nonan-3-ol derivative |
| EP3064490A1 (fr) | 2015-03-06 | 2016-09-07 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Procédé amélioré pour la préparation d'eslicarbazépine et d'acétate d'eslicarbazépine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605897A (en) * | 1991-04-23 | 1997-02-25 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine |
| PT101732B (pt) | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| DE10036289A1 (de) | 2000-07-26 | 2002-02-07 | Bosch Gmbh Robert | Elektronisch kommutierte elektrische Maschine, insbesondere Motor |
| US20050004102A1 (en) * | 2001-11-12 | 2005-01-06 | Markus Schmutz | Monohydroxycarbamazepine for use in the preparation of a medicament for the treatment of affective and attention disorder and neuropathic pain |
-
2004
- 2004-03-31 TW TW093108936A patent/TW200502222A/zh unknown
- 2004-04-01 US US10/550,382 patent/US20070010508A1/en not_active Abandoned
- 2004-04-01 CA CA002520828A patent/CA2520828A1/fr not_active Abandoned
- 2004-04-01 RU RU2005133665/14A patent/RU2367440C2/ru not_active IP Right Cessation
- 2004-04-01 CN CNA2004800091429A patent/CN1767834A/zh active Pending
- 2004-04-01 EP EP04725047A patent/EP1613329A1/fr not_active Withdrawn
- 2004-04-01 MX MXPA05010614A patent/MXPA05010614A/es unknown
- 2004-04-01 NZ NZ542555A patent/NZ542555A/en unknown
- 2004-04-01 JP JP2006505000A patent/JP2006522064A/ja active Pending
- 2004-04-01 KR KR1020057018611A patent/KR20050121235A/ko not_active Application Discontinuation
- 2004-04-01 WO PCT/EP2004/003590 patent/WO2004087168A1/fr active Application Filing
- 2004-04-01 BR BRPI0409151-5A patent/BRPI0409151A/pt not_active IP Right Cessation
- 2004-04-01 AU AU2004226827A patent/AU2004226827B2/en not_active Ceased
-
2005
- 2005-09-26 ZA ZA200507742A patent/ZA200507742B/en unknown
- 2005-09-30 TN TNP2005000246A patent/TNSN05246A1/en unknown
- 2005-10-11 MA MA28546A patent/MA27762A1/fr unknown
- 2005-10-27 IS IS8094A patent/IS8094A/is unknown
- 2005-11-01 NO NO20055098A patent/NO20055098L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004226827B2 (en) | 2008-04-03 |
| MA27762A1 (fr) | 2006-02-01 |
| IS8094A (is) | 2005-10-27 |
| RU2005133665A (ru) | 2006-06-10 |
| TNSN05246A1 (en) | 2007-06-11 |
| NZ542555A (en) | 2009-03-31 |
| CN1767834A (zh) | 2006-05-03 |
| BRPI0409151A (pt) | 2006-03-28 |
| RU2367440C2 (ru) | 2009-09-20 |
| JP2006522064A (ja) | 2006-09-28 |
| NO20055098D0 (no) | 2005-11-01 |
| NO20055098L (no) | 2005-12-22 |
| MXPA05010614A (es) | 2005-11-23 |
| CA2520828A1 (fr) | 2004-10-14 |
| WO2004087168A1 (fr) | 2004-10-14 |
| EP1613329A1 (fr) | 2006-01-11 |
| US20070010508A1 (en) | 2007-01-11 |
| AU2004226827A1 (en) | 2004-10-14 |
| KR20050121235A (ko) | 2005-12-26 |
| TW200502222A (en) | 2005-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200507742B (en) | Use of 10-hydroxy-10, 11-dihydrocarbamazepine for the treatment of affective disorders | |
| JP5082032B2 (ja) | 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物 | |
| Andrews et al. | Venlafaxine: a novel antidepressant that has a dual mechanism of action | |
| US11013721B2 (en) | Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder | |
| US20120028991A1 (en) | Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands | |
| ZA200507439B (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients | |
| CN114727989A (zh) | Gaba-a受体正变构调节剂与nmda拮抗剂、nmda负变构调节剂或nmda部分激动剂的组合 | |
| WO2010126527A1 (fr) | Méthodes de traitement des affections du snc | |
| EP2236157A1 (fr) | Pipampérone et un agent ultérieur pour le traitement des troubles de l'humeur et de l'anxiété | |
| AU2008201166A1 (en) | Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders | |
| Popp et al. | Side effects of and reactions to psychotropic medications | |
| KR20140069120A (ko) | S1p 수용체 조절제를 포함하는 조합물 | |
| Staikowsky et al. | Dextropropoxyphene and the cardiovascular system: About two cases of acute poisoning with cardiac conduction abnormalities | |
| van Boxtel | Drugs acting on the central nervous system | |
| WO2005097138A2 (fr) | Combinaisons comprenant de l'oxcarbazepine pour le traitement de troubles affectifs | |
| David | Oxcarbazepine, Top&mate, Zonisamide, and Levetiracetam: Potential Use in Neuropathic Pain |